Build upon biomarker discovery from next-gen sequencing methods or existing literature to identify DNA methylation patterns and key CpG sites or loci of interest.
Design targets with sequence and strand specificity, and modify selectivity for certain analytes with custom EpiReader proteins. Each protein is then designed and screened to ensure optimal design. Key characterizations include biochemical properties such as target affinity and methylation selectivity.
Interrogate samples to quantify epigenetic patterns with conventional primer design techniques while retaining sequence complexity. Optimized protocols without chemical conversions translate to rapid turnover times and more effective, longitudinal tracking of methylation patterns. Endpoint qPCR, NGS, and single-cell workflows in development.
Utilize high-integrity and high-accuracy EpiReader data to complement existing workflows and inform future development. Track quantitative insights to improve clinical decision-making.
Our core chemistry is conversion-free and involves minimal degradation, improving sensitivity by orders of magnitude.
Our end-to-end workflow is designed for simplicity, allowing for single-day analysis and turnaround for assays built on our platform.
Our custom-designed workflows are suitable for multiplex at scale, allowing analysis at various loci of interest.
DNA methylation is a key chemical modification that is implicated in various processes, ranging from cancer biology to neurodegenerative changes. However, scientists and clinicians lack tools with sufficient sensitivity and reliability to fully characterize methylation patterns. Both bisulfite and enzymatic processes for analysis often damage the DNA samples and lead to a reduction in sequence complexity, making it difficult for characterization of low-input or cell-free DNA samples.